<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02478879</url>
  </required_header>
  <id_info>
    <org_study_id>CP-2015-005</org_study_id>
    <nct_id>NCT02478879</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen</brief_title>
  <official_title>An Open-label Crossover Study to Determine the Patient Preference Between ZP-PTH Patches and Forteo Pens After Daily Treatment for 14 Days in Women 55-85 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zosano Pharma Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zosano Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which of two delivery methods of Parathyroid
      Hormone (PTH) is preferred by patients after 14 days of use for each.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine which of two delivery methods of PTH is preferred
      by patients after 14 days of use for each. Patient preference will be determined by means of
      patient questionnaires at the end of each treatment period and a final questionnaire after
      both treatment periods are complete. Adverse events will also be collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Preference</measure>
    <time_frame>28 days</time_frame>
    <description>The fraction of subjects expressing an overall preference for each treatment based on a 4 point scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (adverse events)</measure>
    <time_frame>28 days</time_frame>
    <description>incidence of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>ZP-PTH Patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal microneedle patch coated with 40 mcg of PTH, applied intracutaneously to the abdomen daily for 30 minutes, 14 days of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FORTEO(R) Pen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Marketed FORTEO 20 mcg, administered daily as a subcutaneous injection to the abdomen or thigh for 14 days of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZP-PTH</intervention_name>
    <description>Patch applied daily for 30 minutes, 14 days</description>
    <arm_group_label>ZP-PTH Patch</arm_group_label>
    <other_name>PTH</other_name>
    <other_name>parathyroid hormone</other_name>
    <other_name>teriparatide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FORTEO</intervention_name>
    <description>Subcutaneous injection administration daily for 14 days</description>
    <arm_group_label>FORTEO(R) Pen</arm_group_label>
    <other_name>PTH</other_name>
    <other_name>FORSTEO</other_name>
    <other_name>teriparatide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal with prior diagnosis of osteoporosis

        Exclusion Criteria:

          -  Significant health issue

          -  previous use of teriparatide

          -  History of Paget's disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugh Coleman, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Convance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Daytona Beach Clinical Research Unit</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2015</study_first_submitted>
  <study_first_submitted_qc>June 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2015</study_first_posted>
  <last_update_submitted>August 21, 2016</last_update_submitted>
  <last_update_submitted_qc>August 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

